Sanofi filed a Form 4 on August 12, 2026, disclosing the automatic conversion of Series B Preferred Stock and a convertible promissory note into common shares of Latigo Biotherapeutics, Inc. (NASDAQ:LTGO) upon the closing of Latigo's initial public offering on August 10, 2026.
Key Highlights
- IPO date: Latigo Biotherapeutics' initial public offering closed on August 10, 2026.
- Preferred Stock conversion: 494,800 shares of Series B Convertible Preferred Stock converted automatically into 494,800 shares of common stock on a one-for-one basis, without payment of consideration.
- Note conversion: 177,978 shares of common stock were issued upon the automatic conversion of a convertible promissory note (principal plus accrued but unpaid interest) at the IPO price.
- Total beneficial ownership after transactions: 672,788 shares of common stock, held indirectly through Sanofi's wholly-owned subsidiaries.
- Ownership fell below 10%: According to the filing, immediately upon consummation of the IPO, Sanofi's beneficial ownership of common stock fell below 10% as a result of the issuance of additional shares.
- Reporting person: Sanofi, identified as a 10% owner prior to the IPO, holds the shares indirectly through various wholly-owned subsidiaries.
Sanofi's Stake in Latigo Biotherapeutics Converts at IPO Closing
According to the Form 4 filed with the SEC on August 12, 2026, Sanofi's pre-existing equity and debt positions in Latigo Biotherapeutics, Inc. were converted into common stock upon the closing of the company's initial public offering on August 10, 2026. Both transactions carried the code "C," indicating conversion, and both are reported as acquisitions of common stock.
The filing discloses that 494,800 shares of Series B Convertible Preferred Stock converted automatically into 494,800 shares of common stock on a one-for-one basis at the IPO closing, with no payment of consideration required. Separately, a convertible promissory note - covering principal and any accrued but unpaid interest - converted automatically into 177,978 shares of common stock at a conversion price equal to the IPO price of the common stock. Following both transactions, Sanofi beneficially owned 672,788 shares of common stock in total, all held indirectly through various wholly-owned subsidiaries.
The filing further states that "immediately upon consummation of the IPO, Sanofi's beneficial ownership of the common stock fell below 10%, as a result of the issuance of additional shares of common stock." The filing notes that convertibility and expiration details for the Preferred Stock and the Note prior to the IPO are described in Sanofi's Form 3, filed with the SEC on August 12, 2026. The Form 4 was signed by Alexandra Roger as attorney-in-fact for Sanofi.
What Was Disclosed
Sanofi reported the automatic conversion of Series B Preferred Stock and a convertible promissory note into a combined 672,788 shares of common stock in Latigo Biotherapeutics upon the August 10, 2026 IPO closing, with beneficial ownership held indirectly and falling below 10% immediately after the IPO.



Please wait processing your request...